Evaluation of Intravenous Posaconazole Dosing and Pharmacokinetic Target Attainment in Pediatric Patients

Limited data exist on intravenous (IV) posaconazole dosing and the risk for hepatotoxicity it confers to children. In this study, we evaluated dosing and resulting trough levels in 10 pediatric patients on IV posaconazole. A therapeutic level in these patients was achieved 95% of the time. We found...

Full description

Saved in:
Bibliographic Details
Published inJournal of the Pediatric Infectious Diseases Society Vol. 8; no. 4; pp. 365 - 367
Main Authors Nickless, Jenna R, Bridger, Kathryn E, Vora, Surabhi B, Brothers, Adam W
Format Journal Article
LanguageEnglish
Published England 25.09.2019
Subjects
Administration, Intravenous
Adolescent
Alanine Transaminase
Antifungal Agents - administration & dosage
Antifungal Agents - pharmacokinetics
Antifungal Agents - therapeutic use
Antifungal Agents - toxicity
Child
Child, Preschool
Drug Monitoring
Humans
Infant
Infant, Newborn
Retrospective Studies
Triazoles - administration & dosage
Triazoles - pharmacokinetics
Triazoles - therapeutic use
Triazoles - toxicity
posaconazole
intravenous
level
hepatotoxicity
child
Online AccessGet full text

Cover

More Information
Summary:Limited data exist on intravenous (IV) posaconazole dosing and the risk for hepatotoxicity it confers to children. In this study, we evaluated dosing and resulting trough levels in 10 pediatric patients on IV posaconazole. A therapeutic level in these patients was achieved 95% of the time. We found a median minimum effective dose of 6.55 mg/kg of body weight. No correlation was found between the duration or posaconazole trough level and an increased alanine transaminase level.
ISSN:2048-7193
2048-7207
DOI:10.1093/jpids/piy094